结核性脑膜炎患者血浆与脑脊液中利奈唑胺的人群药代动力学模型
本研究为LASER-TBM药代动力学子研究,纳入30例结核性脑膜炎成人患者,接受高剂量利福平(35 mg/kg)联合利奈唑胺1200 mg/日共28天后减至600 mg/日。利奈唑胺血浆药代动力学符合一室模型,脑脊液-血浆分配系数随脑脊液总蛋白升高而增大,最高达37%。结论支持继续临床评估利奈唑胺联合高剂量利福平治疗成人结核性脑膜炎。
要点
- 高剂量利福平联用未影响利奈唑胺药代动力学。
- 脑脊液-血浆分配系数在脑脊液总蛋白达1.2 g/L时最大为37%。
- 血浆-脑脊液平衡半衰期约为3.5小时。
核心结论
- 尽管联用高剂量利福平,脑脊液中仍可 readily 检测到利奈唑胺,支持继续临床评估利奈唑胺联合高剂量利福平治疗成人结核性脑膜炎。
研究设计与样本
- LASER-TBM药代动力学子研究,干预组接受高剂量利福平(35 mg/kg)联合利奈唑胺1200 mg/日共28天后减至600 mg/日。
- 30例参与者贡献247份血浆和28份脑脊液观测,中位年龄40岁(范围27-56),中位体重58 kg(范围30-96)。
- 第3天进行密集血浆采样,第28天进行稀疏采样,两次访视均采集腰椎脑脊液样本。
主要发现
- 血浆药代动力学用一室模型描述,含一级吸收和可饱和消除,最大清除率为7.25 L/h,米氏常数为27.2 mg/L。
- 利福平联用持续时间不影响利奈唑胺药代动力学。
- 脑脊液-血浆分配与脑脊液总蛋白相关,至1.2 g/L时分配系数达最大值37%。
- 血浆-脑脊液平衡半衰期约为3.5小时。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Linezolid is evaluated in novel treatment regimens for tuberculous meningitis (TBM). Linezolid pharmacokinetics have not been characterized in this population, particularly in cerebrospinal fluid (CSF), as well as, following its co-administration with high-dose rifampicin. We aimed to characterize linezolid plasma and CSF pharmacokinetics in adults with TBM. METHODS: In the LASER-TBM pharmacokinetic substudy, the intervention groups received high-dose rifampicin (35 mg/kg) plus 1200 mg/day of linezolid for 28 days, which was then reduced to 600 mg/day. Plasma sampling was done on day 3 (intensive) and day 28 (sparse). A lumbar CSF sample was obtained on both visits. RESULTS: Thirty participants contributed 247 plasma and 28 CSF observations. Their median age and weight were 40 years (range, 27-56) and 58 kg (range, 30-96). Plasma pharmacokinetics was described by a 1-compartment model with first-order absorption and saturable elimination. Maximal clearance was 7.25 L/h, and the Michaelis-Menten constant was 27.2 mg/L. Rifampicin cotreatment duration did not affect linezolid pharmacokinetics. CSF-plasma partitioning correlated with CSF total protein up to 1.2 g/L, where the partition coefficient reached a maximal value of 37%. The plasma-CSF equilibration half-life was ∼3.5 hours. CONCLUSIONS: Linezolid was readily detected in CSF despite high-dose rifampicin coadministration. These findings support continued clinical evaluation of linezolid plus high-dose rifampicin for the treatment of TBM in adults. Clinical Trials Registration. ClinicalTrials.gov (NCT03927313).
引用
- Abdelgawad N, Wasserman S, Abdelwahab MT, et al. Linezolid Population Pharmacokinetic Model in Plasma and Cerebrospinal Fluid Among Patients With Tuberculosis Meningitis. J Infect Dis. 2024. PMID: 37740554. doi:10.1093/infdis/jiad413
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。